LAPTM4B and non-small cell lung carcinoma: In summary, our findings delineate a previously unrecognized lysosomal mechanism underlying EGFR-TKI resistance and establish LAPTM4B as a promising therapeutic target for overcoming drug resistance in EGFR-mutant NSCLC.